RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCI SCIE SCOPUS

      Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection

      한글로보기

      https://www.riss.kr/link?id=A107002163

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who wereadmitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receivedarunavir-cobicistat (800–150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 receivedother antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and thecrude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95%confidence interval (CI) 0.04–0.89, p=0.035]. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistatgroup, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortalitythan the controls (OR 0.07, 95% CI 0.01–0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associatedwith a significant survival benefit in critically ill patients with SARS-CoV-2 infection.
      번역하기

      We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who wereadmitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) received...

      We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who wereadmitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receivedarunavir-cobicistat (800–150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 receivedother antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and thecrude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95%confidence interval (CI) 0.04–0.89, p=0.035]. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistatgroup, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortalitythan the controls (OR 0.07, 95% CI 0.01–0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associatedwith a significant survival benefit in critically ill patients with SARS-CoV-2 infection.

      더보기

      참고문헌 (Reference)

      1 Chu CM, "Role of lopinavir/ritonavir in the treatment of SARS : initial virological and clinical findings" 59 : 252-256, 2004

      2 Curran A, "Rezolsta®(darunavir/cobicistat) : first boosted protease inhibitor co-formulated with cobicistat" 17 : 114-120, 2015

      3 Putcharoen O, "Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS" 9 : 5763-5769, 2015

      4 James M. Sanders, "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)" American Medical Association (AMA) 2020

      5 Dong L, "Discovering drugs to treat coronavirus disease 2019(COVID-19)" 14 : 58-60, 2020

      6 Zanon D, "Data on the stability of darunavir/cobicistat suspension after tablet manipulation" 30 : 105552-, 2020

      7 China News Network, "Abidol and darunavir can effectively inhibit coronavirus"

      8 Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19" 382 : 1787-1799, 2020

      1 Chu CM, "Role of lopinavir/ritonavir in the treatment of SARS : initial virological and clinical findings" 59 : 252-256, 2004

      2 Curran A, "Rezolsta®(darunavir/cobicistat) : first boosted protease inhibitor co-formulated with cobicistat" 17 : 114-120, 2015

      3 Putcharoen O, "Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS" 9 : 5763-5769, 2015

      4 James M. Sanders, "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)" American Medical Association (AMA) 2020

      5 Dong L, "Discovering drugs to treat coronavirus disease 2019(COVID-19)" 14 : 58-60, 2020

      6 Zanon D, "Data on the stability of darunavir/cobicistat suspension after tablet manipulation" 30 : 105552-, 2020

      7 China News Network, "Abidol and darunavir can effectively inhibit coronavirus"

      8 Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19" 382 : 1787-1799, 2020

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2011-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2009-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2007-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2005-05-31 학술지등록 한글명 : Yonsei Medical Journal
      외국어명 : Yonsei Medical Journal
      KCI등재
      2005-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2002-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2000-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 1.42 0.3 0.99
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.83 0.72 0.546 0.08
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼